Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2021
Neurocrine sues Lupin over Ingrezza patents
Lawsuit filed
Neurocrine Biosciences filed suit against Lupin, alleging infringement of three patents protecting Ingrezza. Lupin disputed infringement in its ANDA, while Neurocrine sought a judgment and an injunction.
Source excerpt
Lupin detailed within their ANDA their belief that the patents-in-suit are “invalid, unenforceable or will not be infringed by the manufacture, use or sale of Lupin’s generic products.”
filed suit last Friday against defendants Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc., and Lupin Atlantis Holdings S.A. (collectively, Lupin) in the District of Delaware.
The suit came about due to Lupin’s alleged infringement of three patents held by Neurocrine, all of which protect the drug Ingrezza.